Company Overview: Zhuhai Sinochips Bioscience Technology Co., Ltd. (referred to as "Sinochips" below) was founded in August 2005. It is a high-tech enterprise focused on precision medicine diagnosis based on nucleic acid technology. Sinochips is a multinational group company that integrates research and development, production, sales, and related technical services. It uses its unique technology and products to develop a comprehensive international high-end market. In 2018, Sinochips was included in the first batch of high-growth and innovative (unicorn) incubation enterprises in Zhuhai. Sinochips is also the Guangdong Gene Chip Engineering Technology Research Center and has established a research and development institution in the United States. It is actively preparing to establish Sino-US academician workstations and postdoctoral workstations. Main Products (Business Scope): The main products include five series of precision medical products, including 17 registration certificates for in vitro diagnostic reagents and 13 domestically and internationally pioneering products. The scope covers precision diagnosis and treatment of eugenics and eugenic, metabolic diseases, infectious diseases, hepatitis, and tumor-related diseases etc. Core Technology: The core technology platform, including 11 invention patents, is named for the first time domestically and internationally (in Chinese and English) as "a high-sensitivity biosensor gene chip and clinical diagnostic technology". It has developed a technical platform for the entire industry chain of gene chips. The core technology includes preparation technology of biosensor gene chip raw materials, key technology for biosensor gene chip production, high-sensitivity gene amplification system production technology, automatic detection platform technology for gene chips, quality control technology for gene chip mass production, and biological reagent stability and anti-pollution technology. Market Position: At present, the company is the largest manufacturer of in vitro diagnostic biochips in China. The company's products are mainly used in the top three hospitals in China, and it currently cooperates with more than 150 top-tier hospitals, accounting for more than 70% of the top 100 hospitals in China. While occupying an absolute monopoly position in related technology and products domestically, the company has also started to expand into the international market in recent years and has achieved product sales in many countries in Europe and the United States. It is actively expanding and enlarging the overseas market and entering the international medical supply chain system.Our commitment to innovation and excellence has garnered us numerous honors and awards. In 2018, we were recognized as a Unicorn Potential Enterprise by the prestigious 2018 Zhuhai Cultivation and Introduction of High Growth Innovative Enterprises, Unicorn Enterprise Cultivation Pool.Building on our success, we were bestowed the esteemed title of Guangdong Gene Chip Engineering Technology Research Center in 2019, as awarded by the Guangdong Provincial Department of Science and Technology. This recognition underscores our significant contributions to the field.In 2021, we were granted the coveted status of a High-tech Enterprise by the Guangdong Science and Technology Department, Guangdong Finance Department, and Guangdong Taxation Bureau of the State Administration of Taxation. This accolade reflects our dedication to pioneering research and development.Our dedication to innovation and technological advancement is widely recognized. The Guangdong Provincial Department of Industry and Information Technology recognized us as an innovative Small and Medium Enterprise in 2022.As we progress into the future, we are proud to announce that in 2023, we have achieved the status of a Specialized Small and Medium Enterprise, further reinforcing our position as a leading player in the industry.